Eko Launches SENSORA Cardiac Disease Detection Platform

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Endo Announces Peyronie’s Disease Presentation at...

Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today...

Leadership at NHS Hospitals in Leeds...

A watchdog has gone on to say that the...

Developing Dr. CaBot, A Medical Education...

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for...

The medicines regulator of the UK has announced plans...

Eko announced the launch of the SENSORA™ Cardiac Disease Detection Platform. SENSORA™ currently features AI which objectively identifies structural murmurs, a sign of valvular heart disease, and Care Pathway Analytics software that provides downstream visibility and metrics of the patient journey through the healthcare system.

SENSORA™ is a cardiovascular disease detection platform combining the latest advancements in applied machine learning with one of the most ubiquitous medical devices in the world: the stethoscope. By capturing and analysing heart sounds and electrical signals with its digital stethoscopes.

The FDA-cleared SENSORA™ structural murmur detection helps health systems more accurately and consistently identify valvular heart disease (VHD) in patients during a routine visit with the primary care physician. VHD is a life-threatening condition diagnosed in more than 8 million Americans. VHD, when left undetected and untreated, can lead to heart failure, stroke, blood clots, and death. Older adults have a 1 in 10 chance of developing clinically significant VHD. However, more than half (57%) of clinically significant valvular heart disease goes undetected in this population. A primary care physician using SENSORA™ for structural murmur detection more than doubles likelihood of detecting significant VHD.

 

Latest stories

Related stories

Developing Dr. CaBot, A Medical Education Tool That Reasons

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for Medtech Regulatory Reforms

The medicines regulator of the UK has announced plans...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »